Shilpa Medicare announced that the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has issued final approval for grant of marketing authorization for OERIS (Ondansetron Extended-Release Injection, 100 mg/mL).
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.